Improving T cell therapy for pancreatic cancer treatment
Enhancing engineered T cell therapeutic efficacy for the treatment of pancreatic ductal adenocarcinoma
This study is looking at a new way to make special immune cells, called T cells, better at fighting pancreatic cancer by helping them work around the tough conditions in tumors, with the hope of improving survival for patients with this aggressive cancer.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Minnesota NIH-funded |
| Lab location | 1 site (Minneapolis, United States) |
| Project ID | NIH-10902078 on NIH RePORTER |
What this research studies
This research focuses on enhancing the effectiveness of engineered T cell therapies specifically for pancreatic ductal adenocarcinoma (PDA), a highly aggressive form of cancer. The approach involves creating T cells that are designed to target and attack tumor cells while overcoming the suppressive tumor environment that hinders treatment success. By studying how these engineered T cells interact with the tumor microenvironment in animal models, researchers aim to identify factors that improve their ability to fight the cancer. The ultimate goal is to develop a therapy that can significantly improve survival rates for patients with PDA.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with pancreatic ductal adenocarcinoma who may benefit from innovative immunotherapy approaches.
Not a fit: Patients with early-stage pancreatic cancer or those whose cancer has not progressed may not receive direct benefits from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for pancreatic cancer, potentially improving survival rates and quality of life for patients.
How similar studies have performed: Previous research has shown promise in using engineered T cell therapies for other types of cancer, indicating potential for success in this novel application for pancreatic cancer.
Where this research is happening
Minneapolis, United States
- University of Minnesota — Minneapolis, United States (Active)
Researchers
- Principal investigator: Stromnes, Ingunn Margarete — University of Minnesota
- Study coordinator: Stromnes, Ingunn Margarete
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.